EVM
EBS icon

Eaton Vance Management’s Emergent Biosolutions EBS Stock Holding History

Eaton Vance Management’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-2,745
Closed -$120K – 2041
2021
Q4 		$120K Buy
2,745
+782
+40% +$35.4K ﹤0.01% 1762
2021
Q3 		$31K Sell
1,963
-161
-8% -$9.75K ﹤0.01% 1587
2021
Q2 		$133K Sell
2,124
-446,351
-100% -$28.7M ﹤0.01% 1773
2021
Q1 		$41.7M Sell
448,475
-8,293
-2% -$849K 0.06% 297
2020
Q4 		$40.9M Buy
456,768
+77,233
+20% +$7.09M 0.06% 278
2020
Q3 		$39.2M Buy
379,535
+5,451
+1% +$588K 0.07% 246
2020
Q2 		$29.6M Sell
374,084
-25,100
-6% -$1.87M 0.06% 272
2020
Q1 		$23.1M Sell
399,184
-81,500
-17% -$4.7M 0.06% 276
2019
Q4 		$25.9M Buy
480,684
+286,263
+147% +$15.5M 0.05% 287
2019
Q3 		$10.2M Buy
+194,421
New +$9.06M 0.02% 437

Other funds holding EBS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Eaton Vance Management's EBS Position: Q1 2022 in Review

Eaton Vance Management sold out of Emergent Biosolutions (EBS) in Q1 2022, closing a stake of 2,745 shares — an estimated $120K sold.

Eaton Vance Management first reported a position in EBS in Q3 2019 and held it in 10 quarters. The position peaked at $41.7M in Q1 2021. 255 funds tracked by Wall St. Rank hold EBS as of Q1 2022.

  • Eaton Vance Management reported no remaining Emergent Biosolutions position as of Q1 2022 after selling out during the quarter.
  • Eaton Vance Management sold 2,745 Emergent Biosolutions shares in Q1 2022, an estimated $120K.
  • Eaton Vance Management first reported a position in Emergent Biosolutions in Q3 2019 and held it in 10 quarters.
  • Eaton Vance Management's Emergent Biosolutions position peaked at $41.7M in Q1 2021.
  • 255 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q1 2022.

Based on Eaton Vance Management's 13F filing for Q1 2022, filed 16 May 2022.